New hope for kids with severe psoriasis: QLETLI shows promise

NCT ID NCT05803187

Completed Disease control Sponsor: Bio-Thera Solutions Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether QLETLI, a biosimilar of adalimumab, is safe and effective for children and teens aged 4 to 17 with severe plaque psoriasis. A total of 80 participants were followed for 24 weeks. The main goal was to see how much their psoriasis symptoms improved, measured by skin clearance scores.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QLETLI (adalimumab biosimilar)
What this could lead to: If successful, this could provide a safe and effective treatment option for children with severe plaque psoriasis who have not responded to other therapies.
What could go wrong: This is a small, observational study without a comparison group, so results may not be definitive. As a biosimilar, it may carry similar risks to adalimumab, including infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Show contact details

Locations

Shanghai Tenth People's Hospital

Shanghai, Shanghai Municipality, 200072, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.